Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the release of the white paper titled "SmoothX: A Promising New Positive Oral Contrast Agent for CT." Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX™, emphasising its potential to optimize abdominal CT examinations and maximize patient satisfaction. 

Oral contrast agents have long been vital in elevating diagnostic accuracy and effectiveness in medical imaging procedures. With the introduction of SmoothX, Voyageur is offering a positive oral contrast agent that not only enhances diagnostic outcomes but also provides a pleasant taste, enhancing patient satisfaction. 

In a recent blinded study comparing SmoothX with the established oral contrast agent Readi-CAT2, Voyageur conducted a detailed evaluation, demonstrating that SmoothX exhibited nearly identical diagnostic imaging properties. This finding establishes SmoothX as a reliable alternative that maintains the uncompromising standards of image quality required for precise diagnosis. 

Of notable importance is the taste test study conducted alongside the clinical evaluation. The results revealed a remarkable preference for the palatable flavor of SmoothX among the majority of the participants compared to Readi-CAT2. This preference for SmoothX's taste has the potential to translate into heightened patient satisfaction and increased compliance during abdominal CT examinations. 

Voyageur extends heartfelt appreciation to the dedicated team at Canada Diagnostic Centre in Calgary for their invaluable participation in this study. Under the exceptional leadership of Jay Zelazo, MD, FRCPC, Director of CT, along with Jordan Muth, MRT (MR), MRI & CT Manager, and Michelle Holstein, Radiological Technologist, MRT (R) (MR), the study was meticulously executed, contributing significantly to the credibility and reliability of the findings. 

SmoothX represents a leap forward in oral contrast agents for CT imaging, aiming to provide a superior patient experience while ensuring optimal diagnostic outcomes. Voyageur remains steadfast in its commitment to continuous innovation, dedicated to improving the quality of care for patients worldwide.

For more information about SmoothX and other imaging solutions offered by Voyageur, please visit https://voyageurpharmaceuticals.ca/ and contact Ethan Mohan, Voyageur Sales Manager at +1-403-803-0427 or This email address is being protected from spambots. You need JavaScript enabled to view it.. 

About Voyageur Pharmaceuticals Ltd. 

Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium, iodine and carbon Active Pharmaceutical Ingredients (API) and high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium, iodine and carbon contrast imaging market, Voyageur aims to become a key player by producing its own barium, iodine, and fullerene minerals.

Our business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring the validation of our products by regulatory agencies worldwide. As we solidify our presence in the market, we will transition into a high-margin domestic manufacturer of radiology drugs, further expanding our revenue streams.

Voyageur is committed to sustainability and environmental stewardship. We envision a future where carbon neutrality is the norm, and to achieve this, we are building state-of-the-art carbon-neutral infrastructure. By investing in carbon neutral energy sources and sustainable manufacturing practices, we aim to become 100% self-sufficient across all our manufacturing activities. Our commitment to the environment sets us apart as a pioneer in the industry. 

At the core of our operations, Voyageur owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. Additionally, Voyageur holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, USA, further bolstering our position in the industry. Voyageur owns a 100% interest in two battery mineral projects which focus on copper/zinc development. 

Our ambitious vision is to become the first vertically integrated, carbon-neutral company in the imaging contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, we plan to ensure unmatched quality and cost efficiency. We embody the motto of "From the Earth to the Bottle," highlighting our commitment to responsible sourcing and manufacturing practices. 

For Further Information: 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking” Information 

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the effectiveness of SmoothX as an oral contrast agent, the preference of patients for the taste of SmoothX, Voyageur's plans to become carbon neutral and Voyageur's ability to continuously innovate and improve the quality of care for patients worldwide. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.